Lebrikizumab for nummular eczema in adults
Treatments studied
Part of Skin clinical trials.
This study tests whether lebrikizumab, a new injection, can reduce nummular eczema (coin-shaped eczema patches) in adults whose condition hasn't improved with topical steroid creams. It's designed to help people with moderate-to-severe nummular eczema who need a stronger treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with nummular eczema (coin-shaped eczema patches) for at least 6 months
- Your nummular eczema has not improved adequately with topical steroid creams
- You have not previously taken lebrikizumab, dupilumab, tralokinumab, or Janus kinase inhibitors for eczema
- You do not have moderate-to-severe atopic dermatitis (general eczema) at the same time as nummular eczema
- You do not have other active skin conditions like psoriasis or other forms of eczema that could interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study tests whether a drug called lebrikizumab can reduce severe itching and skin bumps caused by prurigo nodularis (a chronic skin condition). The drug works by calming an overactive immune response in the skin.
This study tests a new injected medication called nemolizumab for people with moderate-to-severe eczema (atopic dermatitis) that hasn't been controlled by creams or ointments. The goal is to see if it reduces symptoms like itching and skin inflammation better than a placebo (inactive shot).
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
Hear when a new Nummular Eczema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.